Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Recent Pipeline Progress And Mixed Share Performance Accurately
- If you are wondering whether Syndax Pharmaceuticals is reasonably priced or getting ahead of itself, it helps to start with what the recent share performance and current valuation signals are telling you.
- The stock closed at US$20.34, with a 1 year return of 47.4%. However, the year to date move of a 4.5% decline and a 7 day return of a 1.9% decline suggest recent sentiment has been more cautious.
- Recent news flow around Syndax has focused on its development pipeline and clinical progress. This often influences how investors think about future cash flows and risk. These updates help frame why the strong 1 year return of 47.4% sits alongside weaker 3 year and 5 year returns of a 21.5% decline and a 14.2% decline.
- On our valuation checks, Syndax scores 2 out of 6 for potential undervaluation via different methods, as shown in this value score. We will look at what standard valuation approaches say about the stock before finishing with a more complete way to think about its value.
Syndax Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Syndax Pharmaceuticals Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model looks at the cash Syndax Pharmaceuticals might generate in the future and then discounts those projected cash flows back to today to estimate what the business could be worth right now.
For Syndax, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of $311.22 million, so the story here rests on future cash generation rather than current cash profits.
Analysts and extrapolated estimates point to free cash flow of $55 million in 2026 and $191 million in 2027, with projections extending out to around $473.70 million by 2030. All cash flows are assessed in US$ and then discounted to today to account for risk and the time value of money.
Putting these projections together, the model arrives at an estimated intrinsic value of about $146.55 per share. Compared with the recent share price of $20.34, this suggests the stock is 86.1% undervalued based on these assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Syndax Pharmaceuticals is undervalued by 86.1%. Track this in your watchlist or portfolio, or discover 877 more undervalued stocks based on cash flows.
Approach 2: Syndax Pharmaceuticals Price vs Sales
For companies where earnings are limited or volatile, the P/S ratio is often a useful way to think about value because it ties the share price to current revenue rather than profit, which can be more stable for early stage biotechs.
What counts as a reasonable P/S ratio depends a lot on how quickly revenue is expected to grow and how risky those future sales look. Higher growth and lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually point to a lower one.
Syndax currently trades on a P/S of 15.88x, compared with the Biotechs industry average of 11.66x and a peer average of 11.65x. Simply Wall St also calculates a Fair Ratio of 0.96x for Syndax, which is its proprietary estimate of what the P/S could be given factors like growth expectations, risk profile, profit margins, industry and market cap.
This Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for company specific characteristics rather than assuming all biotechs deserve similar multiples. On this framework, Syndax’s actual P/S of 15.88x sits well above the 0.96x Fair Ratio, which points to the shares looking expensive on this metric.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1449 companies where insiders are betting big on explosive growth.
Upgrade Your Decision Making: Choose your Syndax Pharmaceuticals Narrative
Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you set your own story for Syndax Pharmaceuticals by linking your view on its revenue growth, earnings, margins and risks to a forecast and fair value. You can then compare that to the current price to help decide whether it looks attractive or not, with the Narrative updating as new news or earnings arrive. One investor might build an optimistic Syndax view around the US$56.00 highest analyst target, while another might anchor on the more cautious US$19.00 target, and both can clearly see how their different stories lead to different fair values and potential investment decisions.
Do you think there's more to the story for Syndax Pharmaceuticals? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com